Gemini Therapeutics Inc Aktie News

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at three upcoming investor conferences:

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of the upsized underwritten offering of shares of its common stock and, in lieu of common st...

Disc Medicine receives a "Strong Buy" rating due to significant progress with bitopertin for EPP and XLP treatment. IRON submitted an NDA for bitopertin under Accelerated Approval, supported by positive BEACON and AURORA phase 2 study results showing reduced PPIX and improved QoL. The company earned a rare Commissioner's National Priority Review Voucher (CNPV), potentially expediting FDA review...

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten offering of $220.0 million of shares of its common stock and, in lie...

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline and operational progress and strategic priorities for the rest of 2025 and 2026.

Biotech stocks Disc Medicine and Revolution Medicines jumped Friday after the duo received some of the first CNPVs.

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will present clinical data as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN)...

WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin fo...